Russell Investments Group’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-126,820
| Closed | -$8.69M | – | 3192 |
|
|
2019
Q3 | $8.69M | Sell |
126,820
-51,536
| -29% | -$3.54M | 0.02% | 918 |
|
|
2019
Q2 | $10.2M | Sell |
178,356
-9,473
| -5% | -$561K | 0.02% | 876 |
|
|
2019
Q1 | $13.1M | Buy |
187,829
+78,113
| +71% | +$5.79M | 0.02% | 762 |
|
|
2018
Q4 | $7.02M | Buy |
109,716
+20,305
| +23% | +$1.42M | 0.02% | 978 |
|
|
2018
Q3 | $6.26M | Buy |
89,411
+51,653
| +137% | +$3.02M | 0.01% | 1189 |
|
|
2018
Q2 | $1.9M | Sell |
37,758
-4,691
| -11% | -$186K | ﹤0.01% | 1782 |
|
|
2018
Q1 | $1.33M | Buy |
42,449
+38,179
| +894% | +$1.27M | ﹤0.01% | 2068 |
|
|
2017
Q4 | $150K | Sell |
4,270
-18,400
| -81% | -$587K | ﹤0.01% | 2717 |
|
|
2017
Q3 | $727K | Buy |
22,670
+6,304
| +39% | +$199K | ﹤0.01% | 2296 |
|
|
2017
Q2 | $533K | Sell |
16,366
-7,956
| -33% | -$252K | ﹤0.01% | 2385 |
|
|
2017
Q1 | $766K | Buy |
24,322
+4,925
| +25% | +$146K | ﹤0.01% | 2243 |
|
|
2016
Q4 | $575K | Buy |
+19,397
| New | +$591K | ﹤0.01% | 2414 |
|
Russell Investments Group's GHDX Position: Q4 2019 in Review
Russell Investments Group sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 126,820 shares — an estimated $8.69M sold.
Russell Investments Group first reported a position in GHDX in Q4 2016 and held it in 12 quarters. The position peaked at $13.1M in Q1 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Russell Investments Group reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Russell Investments Group sold 126,820 Genomic Health, Inc. shares in Q4 2019, an estimated $8.69M.
- Russell Investments Group first reported a position in Genomic Health, Inc. in Q4 2016 and held it in 12 quarters.
- Russell Investments Group's Genomic Health, Inc. position peaked at $13.1M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Russell Investments Group's 13F filing for Q4 2019, filed 29 Jan 2020.